FDA OKs expanded use of Glaxo’s Zejula

The FDA has approved GlaxoSmithKline’s (NYSE:GSK) supplemental marketing application for Zejula (niraparib) for the maintenance treatment of women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.

The PARP inhibitor was first approved in the U.S. in March 2017 for women with recurrent ovarian cancer.

Shares up 1% after hours.

https://seekingalpha.com/news/3566450-fda-oks-expanded-use-of-glaxos-zejula